New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
09:28 EDTMNKD MannKind volatility expected to move on FDA approval of Afrezza
MannKind volatility is expected to move after company confirms FDA approval of Afrezza inhalation powder to improve glycemic control in adult patients with diabetes. Overall option implied volatility of 80 is below its 26-week average of 102 according to Track Data, suggesting decreasing price movement.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use